Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

In mice, the combination therapy not only improved the health of aging mice, but also extended their lifespan by around 30 ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

“Low-grade serous ovarian cancer is a rare and highly recurrent ... LSGOC and changing the treatment possibilities for RAS/MAPK-pathway-driven cancers. We now need to build on this milestone ...

Pharmacogenomics. 2014;15(11):1507-1518. Taken together, these studies have firmly established RAF, PI3K and RAL signaling as key downstream effectors of KRAS that promote lung tumorigenesis.

Detailed price information for Erasca Inc (ERAS-Q) from The Globe and Mail including charting and trades.